Amarin Corp Plc (AMRN)

[sstyles]

From the Bloomberg law article:

"The new ruling, which places a greater emphasis on the label itself rather than just the press releases, marks a low for generics relying on the routine practice of carving out certain uses of copycat drugs to avoid infringement of name brand products, and might actually have been worse than the original decision said Scott Lassman an FDA law and policy attorney with Lassman Law.

"It's going to make it more difficult for companies to avoid infringment through standard carve outs," Lassman said.